Commencement of Phase 1 Clinical Trial studying MYMD-1Posted by On

Tampa, Florida- July 6, 2019- MYMD™ Pharmaceuticals, Inc. announced the commencement of its Phase 1 Clinical Trial studying MYMD-1, the Company’s first-in-class small molecule to suppress TNF-α. MYMD-1 is the first nontoxic small molecule TNF-α inhibitor to cross brain blood barrier. With completion of dosing of the initial patient cohort in the Company’s Phase 1 study captioned   “A Double-blind, Placebo-controlled, Randomized, First-in-human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1”, the Company is advancing its Phase 1 study while planning its Phase 2 human clinical trials in diabetes, multiple sclerosis, cancer, anxiety/ depression and frailty (age reversal).

Uncategorized